RayzeBio, Inc. Common Stock – NASDAQ:RYZB
Market closed
Open in 2 days
RayzeBio, Inc. Common Stock stock price monthly change
+0.74%
month
RayzeBio, Inc. Common Stock stock price quarterly change
+208.25%
quarter
RayzeBio, Inc. Common Stock key metrics
Market Cap | 3.75B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | -58.73M |
Income | -53.34M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRayzeBio, Inc. Common Stock stock price history
RayzeBio, Inc. Common Stock stock forecast
RayzeBio, Inc. Common Stock financial statements
| Sep 2023 | 0 | -18.19M |
|---|
| 2023-11-13 | -0.69 | -1.26 |
|---|
| Sep 2023 | 603513000 | 28.19M | 4.67% |
|---|
| Sep 2023 | -17.26M | -75.53M | 311.55M |
|---|
RayzeBio, Inc. Common Stock alternative data
| Oct 2023 | 88 |
|---|---|
| Nov 2023 | 88 |
| Dec 2023 | 88 |
| Jan 2024 | 88 |
| Feb 2024 | 88 |
| Apr 2024 | 88 |
| May 2024 | 88 |
| Jun 2024 | 88 |
| Jul 2024 | 88 |
RayzeBio, Inc. Common Stock other data
RayzeBio: New IPO With Good Data And Solid Premise
RayzeBio: Initiating Coverage With Buy Rating And A Price Target Of $43
Rare Stock Picks In September 2023 - From 32 Discerning Analysts
RayzeBio: Raising The Bar In Solid Tumor Radiotherapy
U.S. IPO Weekly Recap: Arm Trades Up After Raising Nearly $5 Billion In 2023's Largest IPO To Date
-
When is RayzeBio, Inc. Common Stock's next earnings date?
Unfortunately, RayzeBio, Inc. Common Stock's (RYZB) next earnings date is currently unknown.
-
Does RayzeBio, Inc. Common Stock pay dividends?
No, RayzeBio, Inc. Common Stock does not pay dividends.
-
How much money does RayzeBio, Inc. Common Stock make?
RayzeBio, Inc. Common Stock has a market capitalization of 3.75B. RayzeBio, Inc. Common Stock made a loss 68.6M US dollars in net income (profit) last year or -$1.26 on an earnings per share basis.
-
What is RayzeBio, Inc. Common Stock's stock symbol?
RayzeBio, Inc. Common Stock is traded on the NASDAQ under the ticker symbol "RYZB".
-
What is RayzeBio, Inc. Common Stock's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of RayzeBio, Inc. Common Stock?
Shares of RayzeBio, Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does RayzeBio, Inc. Common Stock have?
As Jul 2024, RayzeBio, Inc. Common Stock employs 88 workers.
-
When RayzeBio, Inc. Common Stock went public?
RayzeBio, Inc. Common Stock is publicly traded company for just a year since IPO on 15 Sep 2023.
RayzeBio, Inc. Common Stock company profile:
Exchange:
NASDAQ
Full time employees:
88
Industry:
Biotechnology
Sector:
Healthcare
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
,
CIK: 0001825367
ISIN: US75525N1072
CUSIP: 75525N107
